Medlab Clinical

Medlab CEO Dr Sean Hall

Medlab Clinical has been granted patent protection for its NanoCelle drug-delivery technology by the US Patent & Trademark Office.

CEO Dr Sean Hall said the patent, titled “Transmucosal and transdermal delivery systems”, gives Medlab “the green light to pursue potential partnering opportunities in the largest and most powerful marketplace in the world”.

Patents have now been granted in Australia, New Zealand, Canada, the US and 37 European countries, with patent protection requested in Hong Kong and another being examined in Singapore.

Helius Therapeutics

New Zealand medicinal cannabis company Helius Therapeutics has appointed Marten Vos as its new director of research & development.

Helius Therapeutics director of research & development Marten Vos

Vos has more than 25 years’ experience in R&D and technical work, including a 12-year stint at Douglas Pharmaceuticals heading its pharmaceutical and natural health development teams.

Helius Therapeutics chief executive Carmen Doran said: “Helius is squarely focused on building and driving its R&D capability, with this new senior role reflecting just that. Successfully competing on the world stage means we need to be a leader in the R&D space, delivering high-quality, next-generation medicinal cannabis therapeutics.”

The new appointment comes after Helius and Auckland University of Technology signed an agreement which enables R&D collaboration.

Creso Pharma

Creso Pharma’s wholly owned subsidiary Halucenex Life Sciences has announced its psilocybin active pharmaceutical ingredient (API) has received positive lab results and been deemed safe for human consumption. 

Halucenex completed all USP 61 and USP 62 stability testing requirements with a favourable result, showing superior concentration in GMP-grade psilocybin with minor impurity levels. 

Stability testing is used to determine whether the quality of a drug is altered over a length of time by factors such as light, temperature and humidity. 

The results mark a milestone for the company’s planned Phase II clinical trial on the efficacy of its API on treatment-resistant Post Traumatic Stress Disorder.